Nocturnal baricitinib administration leads to rapid drug responses in rheumatoid arthritis: a multicenter non-randomized controlled study
Authors' conclusion
Chronotherapy targeting cytokine secretion resulted in rapid drug response, proposing a new potential application for JAK inhibitors.
Study context
- Population
- Patients with rheumatoid arthritis (RA)
- Participants
- 122 patients
- Comparison
- Baricitinib 2 mg or 4 mg administered in the evening vs in the morning
- Primary endpoint
- ACR20
- Follow-up
- Week 12
Methodological detailsmulticentre, propensity score inverse probability of treatment weighted, 52-week
- Multicentre
- Propensity score inverse probability of treatment weighted
- 52-week
Primary result
As reported in the abstract
BAR4EVE vs BAR4MORN: P < 0.001 · BAR2EVE vs BAR2MORN: P = 0.10
Secondary outcomes
ACR20 and ACR50, BAR2EVE vs BAR2MORN · ACR20 weeks 4, 24 and 52; ACR50 weeks 4 and 12
- BAR2EVE demonstrated higher ACR20 at weeks 4, 24, and 52 and ACR50 at weeks 4 and 12 than BAR2MORN
ACR20/50 and ACR70, BAR4EVE vs BAR4MORN · ACR20/50 weeks 4, 8 and 12; ACR70 weeks 8, 12 and 24
- BAR4EVE demonstrated higher ACR20/50 at weeks 4, 8, and 12 and ACR70 at weeks 8, 12, and 24 than BAR4MORN
Clinical disease activity index (CDAI) change, BAR4EVE vs BAR4MORN · weeks 4 and 8
- CDAI changes significantly reduced in BAR4EVE than in BAR4MORN at weeks 4 and 8
Original publication
Nocturnal baricitinib administration leads to rapid drug responses in rheumatoid arthritis: a multicenter non-randomized controlled study. Arthritis Res Ther. Published 17 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →